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Early Low-grade Gastric MALToma Rarely Transforms
Into Diffuse Large Cell Lymphoma or Progresses
Beyond the Stomach and Regional Lymph Nodes
Ting-Yun Liu,1 Pei-Han Dei,1 Sung-Hsin Kuo,2 Chung-Wu Lin1*
Background/Purpose: Gastric mucosa-associated lymphoid tissue lymphoma (MALToma) usually pres-
ents at an early stage involving only the stomach and/or regional lymph nodes. Although a sequential
transformation from low-grade gastric MALToma (GM) to high-grade GM to secondary diffuse large B-cell
lymphoma (DLBCL) is commonly assumed, documented cases of transformation are rare. We aim to de-
termine the frequency of transformation.
Methods: We identified 55 early low-grade GMs, 18 early high-grade GMs, and 13 advanced GMs at the
National Taiwan University Hospital from 1995 to 2005. The median follow-up time was 59 months.
Results: We found that only one early low-grade GM and two early high-grade GMs transformed into second-
ary DLBCLs and progressed outside the stomach and regional lymph nodes. Significantly, we identified 13
low-grade GMs that were refractory to Helicobacter eradication therapy or relapsed after initial response.
All 13 cases had been followed-up for at least 3 years without development of secondary DLBCLs. The 
frequency of transformation for early low-grade GM was less than 2% (1/55). Although two lymphoma-
unrelated mortalities were identified, none of the 55 patients with early-low grade GMs died of the disease.
Conclusion: Compared with chronic lymphocytic leukemia, which has a 16% transformation rate and a
median transformation time of 24 months, we conclude that early low-grade GM rarely transforms into
secondary DLBCL or progresses beyond the stomach. Without transformation or progression, patients
with early low-grade GM rarely die of the disease and should be treated conservatively.
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Gastric mucosa-associated lymphoid tissue lym-
phoma (MALToma) is an extranodal lymphoma,
derived from memory B cells of the marginal
zone. The lymphoma depends on Helicobacter pylori
for growth.1 About 70% of gastric MALToma
(GM) can be cured by H. pylori eradication therapy
(HPET) with antibiotics, but cases with API2-
MALT1 fusion due to t(11;18) (q21;q21) or with
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nuclear expression of nuclear factor kappa B or 
B cell lymphoma 10 are unresponsive.2
Most GMs present at an early stage confined
to the stomach or regional lymph nodes, and have
an excellent prognosis. Upon histopathological
examination, these low-grade GMs are composed
chiefly of centrocyte-like lymphoid cells that often
show monocytoid or plasmacytoid differentiation.3
In addition, centroblasts or large lymphoid cells
are commonly seen. When focal aggregates of large
cells are identified, a diagnosis of high-grade GM is
made, although the clinical behavior of high-grade
GMs may not differ from that of low-grade GMs.4−6
With diffuse infiltrates of large cells and only
residual GM-like areas, a diagnosis of secondary
diffuse large B cell lymphoma (DLBCL) is made.7
Because of these histopathological observa-
tions, a sequential development from low-grade
GM to high-grade GM, to secondary DLBCL is
commonly assumed,8−10 despite rare case reports
that suggest otherwise.11 With this assumption,
aggressive treatment of low-grade GM seems im-
perative to prevent secondary DLBCL. It is there-
fore necessary to document the frequency of diffuse
large cell transformation and critically evaluate the
hypothesis of sequential transformation.
Here, we report our experience with GM.
Compared with chronic lymphocytic leukemia,
early low-grade GM rarely transforms into sec-
ondary DLBCL or progresses outside the stom-
ach and regional lymph nodes. This finding sets
constraints on the sequential model of GM, and
has implication on its clinical management.
Methods
Patients and samples
This study was approved by the ethics committee of
National Taiwan University Hospital. From 1995 to
2005, there were 55 early low-grade GMs, 18 early
high-grade GMs, 13 advanced GMs, eight early
secondary DLBCLs, and 28 early de novo DLBCLs
in the lymphoma database at the Department 
of Pathology of National Taiwan University
Hospital. All were medically treated, ie, with HPET,
chemotherapy, anti-CD20, or a combination of
these methods. Cases receiving gastrectomy were
excluded.
The diagnosis of low-grade GM was based on
initial biopsy and the World Health Organisation
criteria of centrocyte-like infiltrates and lymphoep-
ithelial lesions, without clusters or sheets of large
cells. High-grade GM was based on the initial
biopsy that showed a low-grade GM with clusters
of large cells less than 20% of total lymphoma
cells. Patients with secondary or de novo DLBCL
had diffuse infiltrates of large cells in the initial
biopsy. Coexisting GM was found in either the
initial or follow-up biopsies in secondary DLBCL,
but not in de novo DLBCL. Immunohistochemical
stains for CD20 and CD3 were parts of routine
diagnostic workup. Detection of H. pylori infec-
tion was based on a combination of Diff-Quik
stain for Helicobacter and the urease test.
Staging procedures included physical exami-
nation, routine laboratory tests, inspection of
Waldeyer’s ring, chest radiography, chest and ab-
dominal computed tomography scans, small bowel
series, barium enema study of the colon and rec-
tum, and bone marrow aspiration and biopsy.
Cases in the early stage had involvement of the
stomach and regional lymph nodes only (stage
IE and stage IIE1 of the modified Ann Arbor sys-
tem). Cases in the advanced stage had involvement
beyond the regional lymph nodes.
Most patients with early GM were treated with
HPET, typically amoxicillin, metronidazole, and
either bismuth subcitrate or omeprazole for 2–4
weeks. They were followed by four to six endo-
scopic biopsies every 6–12 weeks until histologi-
cal remission. Most patients with advanced GM
and early secondary or de novo DLBCL were treated
with chemotherapy, such as R-CHOP (Rituximab,
cyclophosphamide, adriamycin, vincristine, and
prednisolone).
The median follow-up time was 61 months for
early low-grade GMs, 32 months for early high-
grade GMs, 62 months for advanced GMs, and
22 months for DLBCLs.
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Statistical analysis
The Mann-Whitney U test and the Kruskal-Wallis
test were used for two-sample and multiple-sample
comparison of continuous data, respectively. The
Fisher’s test was used for two-sample comparison
of categorical data. Survival analysis was performed
using the Kaplan-Meier method.
Results
Early low-grade, early high-grade, and
advanced GM have similar age distributions
We included 55 early low-grade GMs, 18 early
high-grade GMs, 13 advanced GMs, eight early
secondary DLBCLs, and 28 early de novo DLBCLs
in this study (Table 1). The median age of onset
was 58 years for early low-grade GM, 58 years for
early high-grade GM, 59 years for advanced GM,
36 years for early secondary DLBCL, and 66 years
for early de novo DLBCL.
The only significant difference was between
early secondary DLBCL and early de novo DLBCL
(36 vs. 66 years, p = 0.01 by the Mann-Whitney U
test, Figure 1A), suggesting they are distinct entities.
Early GM as a group had similar age distribution
(p = 0.67 by one-way nonparametric analysis of
variance, Figure 1B), and did not differ signifi-
cantly from either early secondary DLBCL or
early de novo DLBCL.
These observations do not support a sequen-
tial evolution from early low-grade GM, via early
high-grade GM, to advanced GM or early second-
ary DLBCL.
Only one early low-grade GM transformed
into DLBCL and progressed outside the
stomach and regional lymph nodes
Only one out of 55 patients had an early low-
grade GM which transformed into DLBCL. The
remaining 54 cases did not progress, including
41 cases that achieved remission in 3 years and
Table 1. Clinical features of gastric lymphoma
No of Age of Sex Helicobacter Mortality HPET: both: 
case (n) onset (yr) (M:F) positive (%) (n) R-CHOP* (%)
Early low-grade GM
Remission within 3 years 41 58 (26–85) 12:29 99 2§ 90:5:5
Refractory or relapsed 13 61(33–89) 6:7 77 0 31:69:0
Transformed 1 54 1:0 100 0 0:100:0
Advanced GM
Not transformed† 13 59 (39–77) 9:4 69 5 8:25:67
Early high-grade GM
Remission 16 58 (37–76) 8:8 86 2§ 46:27:27
Transformed 2 67 (53–81) 0:2 50 1 50:0:50
Early secondary DLBCL‡
Non-progressive 6 36 (19–66) 3:3 100 1§ 17:33:50
Progressive 2 52 (35–70) 1:1 50 2 0:0:100
Early de novo DLBCL‡
Non-progressive 22 66 (45–93) 9:13 30 1§ 9:0:91
Progressive 6 54 (41–70) 3:3 50 3 0:0:100
*Cases treated with HPET alone, HPET followed by chemotherapy, or, chemotherapy alone (%); †no transformed cases; no refractory
or relapsed cases; ‡for early DLBCL, cases were divided into those progressed and did not progress outside the stomach and regional
lymph nodes; §death unrelated to lymphoma. GM = Gastric MALToma; HPET = Helicobacter pylori eradication therapy; R-CHOP =
rituximab, cyclophosphamide, adriamycin, vincristine, and prednisolone chemotherapy; DLBCL = diffuse large B-cell lymphoma.
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never relapsed, and 13 cases that were either re-
fractory or relapsed after initial responses. These
54 cases did not transform into high-grade GM
or DLBCL (Table 1).
Notably, transformation into DLBCL or pro-
gression outside the stomach did not develop 
in any of 13 low-grade GMs that were refractory
to initial treatment or had relapses after initial re-
sponses. Since these 13 cases had been regularly
monitored by endoscopic biopsies for at least 
3 years, this finding was additional evidence
against a sequential evolution from early low-
grade GM, via early high-grade GM, to advanced
GM or secondary DLBCL.
The only case with transformation was a 
54-year-old male patient. His lesion subsided
after HPET in 4 months, but biopsy of a neck
mass showed DLBCL 7 months later (Figure 2).
He received CHOP, achieved remission, and was
alive at the last follow-up, 3 years after the initial
presentation (Table 2).
Two cases with early high-grade GM
transformed into DLBCL and progressed
outside the stomach within 1 year of diagnosis
Out of 18 patients with early high-grade GM, 
16 cases did not progress outside the stomach or 
regional lymph nodes and did not transform
into DLBCL; furthermore, all 16 cases achieved
remission without recurrence (Table 1). However,
two cases transformed and progressed outside the
stomach (Table 2).
The first case was a 53-year-old male patient.
After antibiotic treatment, the gastric lesion went
into remission in 2 months. Yet he developed
DLBCL of the small intestine and the spleen 
6 months later.16 The patient was lost to follow-up.
The second case was an 81-year-old female
patient. Remission was achieved with chemother-
apy in 3 months, but enlargement of para-aortic
lymph nodes and focal bone marrow involvement
due to infiltration of large lymphoid cells was soon
noted. She died with fever and multiple organ
failure 5 months after chemotherapy.
Interestingly, both early high-grade GMs had
DLBCLs outside the stomach within 1 year, as
did the sole case of early low-grade GM that
transformed into DLBCL outside the stomach
(Table 2).12
Patients with early secondary DLBCL might
revert to GM after treatment
Out of 36 cases of early DLBCL in this study, eight
early secondary DLBCLs were identified (Table 2).
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Figure 1. Age onset is similar among low-grade gastric mucosa-associated lymphoid tissue lymphoma (GM), high-grade
GM, and secondary diffuse large B cell lymphoma (DLBCL). (A) Early secondary DLBCL is compared with early de novo
DLBCL. (B) Early low-grade GM, early high-grade GM, and advanced GM are compared. The median age of onset is 
58 for early low-grade GM, 58 for early high-grade GM, 59 for advanced GM, 36 for early secondary DLBCL, and 66 for
early de novo DLBCL.
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Figure 2. Histopathology of transformation and reversion. (A) Low-grade gastric mucosa-associated lymphoid tissue 
lymphoma of (E) small lymphoid cells transformed into (B) a diffuse large B cell lymphoma in the lymph node composed
of (F) mostly medium to large lymphoid cells with prominent nucleoli. (C) A diffuse large B cell lymphoma with (G) blas-
tic or large lymphoid cells reverted into (D) a low-grade gastric mucosa-associated lymphoid tissue lymphoma of 
(H) small lymphoid cells. A–D: low-power view at 100˜; E–H: the corresponding high-power view at 100˜. An Olympus
B˜60 microscope with a 10˜/22 ocular lens, and a 10˜/0.40 or 100˜/0.17 objective lens were used (Olympus, 
Tokyo, Japan).
A component of GM was found in the initial bi-
opsy of one early secondary DLBCL. In the remain-
ing seven early secondary DLBCLs, a component
of GM was not found in the initial biopsy but in
the follow-up biopsies after treatment, including
six high-grade GMs and one low-grade GM (Figure
2). Therapy-induced reversion of early DLBCL into
high-grade GM was therefore quite common
(17%, 6/36).
No patients with early low-grade GMs died
from the lymphoma
The mean survival times for early low-grade GM
and advanced GM were 162 months and 89
months, respectively (Figure 3). The mean remis-
sion times were 10 months for early low-grade
GM and 27 months for advanced GM.
None of the 55 patients with early low-grade
GM died from lymphoma and only two died of
causes unrelated to lymphoma. In contrast, five
out of 13 patients with advanced GM died be-
cause of lymphoma (Table 1).
Early high-grade GM and early secondary
DLBCL had similar remission and 
survival curves
Early high-grade GM, early secondary DLBCL, and
early de novo DLBCL had similar remission and
survival curves (Figure 4). The estimated mean re-
mission times were 4, 10, and 6 months respec-
tively, and the estimated mean survival times were
75, 70, and 104 months respectively. Although the
treatment regimens were not exactly comparable,
we found no evidence that responses to treatments
were different among these three groups.
Discussion
GM is an unusual lymphoma because of its 
dependency on H. pylori.1 Most GMs have a 
low-grade morphology, characterized by the pre-
dominance of centrocyte-like, monocytoid, and
plasmacytoid cells.3 As commonly assumed, a
low-grade GM might evolve into a high-grade
GM through focal accumulations of large lym-
phoid cells, and a high-grade GM might transform
into a secondary DLBCL through diffuse infil-
trates of large lymphoid cells.8−10 Despite this as-
sumption, only rare cases have been reported to
develop transformation.13,14
Our initial observation of similar age distribu-
tions between GMs and secondary DLBCLs raised
questions about this sequential model, which
could only be true if the preceding phase of GM
in secondary DLBCL is extremely short.
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In 55 early low-grade and 18 high-grade GMs,
transformation into DLBCL or progression be-
yond the stomach and regional lymph nodes were
found in only three cases. Importantly, transfor-
mation or progression was found in none of the
13 low-grade GMs that were refractory to HPET
or had relapses after HPET, and had been moni-
tored by endoscopic biopsies regularly for at least
3 years. Therefore, most early GMs are stable and
do not transform into secondary DLBCLs.
Interestingly, three rare cases of transformation
and progression all occurred within 1 year. This
phenomenon of rapid transformation was also
reported by other groups15 and specific strains of
Helicobacter might have the ability to induce such
a rapid transformation.16
Our study on transformation showed that
two instances of transformation were noted out
of 18 early high-grade GMs (11% or 2/18), and
one instance of transformation was noted out of
55 early low-grade GMs (2% or 1/55). To com-
plement the study of transformation, we also 
investigated the phenomenon of reversion from
early DLBCL to early GM. Six cases reverted into
high-grade GMs (17%, or 6/36 early DLBCLs)
and one case reverted into low-grade GM (3% 
or 1/36 early DLBCLs). Taking both transforma-
tion and reversion together, it seems that early
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Figure 3. (A) Remission and (B) survival curves of early low-grade gastric mucosa-associated lymphoid tissue lymphoma
and advanced gastric mucosa-associated lymphoid tissue lymphoma. GM = Gastric mucosa-associated lymphoid tissue
lymphoma; DLBCL = diffuse large B-cell lymphoma.
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Figure 4. Early high-grade gastric mucosa-associated lymphoid tissue lymphoma, early de novo diffuse large B cell lym-
phoma, and early secondary diffuse large B cell lymphoma have similar (A) remission and (B) survival curves. GM = Gastric
mucosa-associated lymphoid tissue lymphoma; DLBCL = diffuse large B-cell lymphoma.
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high-grade GM and secondary DLBCL are rather
similar and may interconvert into each other,
whereas early low-grade GM is a distinct entity
with rare interconversions with early high-grade
GM and DLBCL.
Transformation is an interesting phenomenon
best studied in chronic lymphocytic leukemia
(CLL),17 but also documented in follicular lym-
phoma, marginal zone lymphoma, and Hodgkin
lymphoma.18,19 Even for CLL alone, various types
of transformation can be identified. In a recent
report, the incidence of transformation into
DLBCL, which carries a grave prognosis, is 16.2%
and the median time to transformation is 23.0
months.20,21 For CLL, expression of CD38, ab-
sence of del13q14, and usage of IGHV4-39 are
risk factors for transformation.17,20,21
In summary, we found that only one out of
55 cases of early low-grade GMs transformed into
DLBCL (2% or 1/55) with a median follow-up
time of 61 months. Two transformations were doc-
umented in 18 early high-grade GMs (11% or
2/18). On the other hand, out of 36 early DLBCLs,
we identified six instances of reversion into early
high-grade GMs (17% or 6/36) and one instance
of reversion into low-grade GM (3% or 1/36).
Isolation of the MALToma and DLBCL compo-
nents with laser capture microdissection followed
by sequencing of the immunoglobulin heavy
chain variable regions would be required to prove
the clonality. Our data on the occurrences of trans-
formation or reversion suggest that low-grade GM
is a distinct entity whereas high-grade GM and
secondary DLBCL are rather similar, supporting
the current WHO position on not grading GM.
Since early low-grade GM rarely transforms into
DLBCL, it should be managed conservatively.22
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